Impact BioMedical (IBO) said Monday it agreed to merge with Hong Kong-based pharmaceutical group Dr. Ashleys that will result in a newly formed entity under "Dr Ashleys Limited."
Shares of Impact jumped 350%, with intraday trading volume of over 379 million against a daily average of about 6.81 million.
Cidara Therapeutics (CDTX) shares doubled after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults met its primary and all secondary efficacy endpoints for all dose groups.
RBC raised its price target on the stock to $75 from $35 while maintaining its outperform rating.
More than 5.25 million shares of Cidara traded intraday, compared with a daily average of about 171,000.
SpartanNash (SPTN) said it agreed to be acquired by C&S Wholesale Grocers for $26.90 per share for a total purchase price of $1.77 billion.
Shares of SpartanNash soared 50% as trading volume surged to over 7.1 million shares from a daily average of roughly 323,000.
Price: 1.70, Change: +1.34, Percent Change: +369.51
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。